Literature DB >> 9145745

Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia.

D W Beezhold1, S Slaughter, M K Hayden, M Matushek, C Nathan, G M Trenholme, R A Weinstein.   

Abstract

To assess the prevalence of skin and rectal colonization by vancomycin-resistant enterococci (VRE) in hospitalized bacteremic patients and to determine the relation between colonization and bacteremia, we compared 14 case patients who had bacteremia due to VRE with 30 control patients who had bacteremia due to other pathogens. Rectal colonization and skin (inguinal area and/or antecubital fossa) colonization with VRE were common among both case patients (100% had rectal colonization, and 86% had skin colonization) and control patients (37% had rectal colonization and 23% had skin colonization). Among patients with rectal colonization, skin colonization was more common when diarrhea or fecal incontinence was present. The bloodstream cleared without appropriate antimicrobial therapy in nine of the 14 patients with bacteremia due to VRE. The high prevalence of skin colonization with VRE may increase the risk of catheter-related sepsis, cross-infection, or blood culture contamination (which may explain the frequent spontaneous resolution of bacteremia due to VRE).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145745     DOI: 10.1093/clind/24.4.704

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

3.  Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.

Authors:  L R Baden; I A Critchley; D F Sahm; W So; M Gedde; S Porter; R C Moellering; G Eliopoulos
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 4.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 6.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 7.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

Review 8.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Bacterial burden is associated with increased transmission to health care workers from patients colonized with vancomycin-resistant Enterococcus.

Authors:  Sarah S Jackson; Anthony D Harris; Laurence S Magder; Kristen A Stafford; J Kristie Johnson; Loren G Miller; David P Calfee; Kerri A Thom
Journal:  Am J Infect Control       Date:  2018-09-26       Impact factor: 2.918

10.  Prior inpatient admission increases the risk of post-operative infection in hepatobiliary and pancreatic surgery.

Authors:  Zachary M Dong; Alexis P Chidi; Julie Goswami; Katrina Han; Richard L Simmons; Matthew R Rosengart; Allan Tsung
Journal:  HPB (Oxford)       Date:  2015-09-03       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.